Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kalbe Farma TbkFRA:LCLA -3.57%77 ROC (Joel Greenblatt) % is 30.43% as of Mar. 2026, which is 7% above its 10-year median of 28.41. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.10 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 983 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 71.11% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. PT Kalbe Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 30.43%.
The historical rank and industry rank for PT Kalbe Farma Tbk's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:LCLA'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 20.99 Med: 28.41 Max: 36.55
Current: 26.41
During the past 13 years, PT Kalbe Farma Tbk's highest ROC (Joel Greenblatt) % was 36.55%. The lowest was 20.99%. And the median was 28.41%.
FRA:LCLA's ROC (Joel Greenblatt) % is ranked better than 71.11% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs FRA:LCLA: 26.41
PT Kalbe Farma Tbk's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -2.80% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
PT Kalbe Farma Tbk ROC (Joel Greenblatt) % Related Terms
PT Kalbe Farma Tbk ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 30.43% mean?
PT Kalbe Farma Tbk (FRA:LCLA) has a ROC (Joel Greenblatt) % of 30.43% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on PT Kalbe Farma Tbk and its competitors. This is near median its historical median of 28.41. Over the past decade, PT Kalbe Farma Tbk's ROC (Joel Greenblatt) % has ranged from 20.99 to 36.55. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #284 out of 983 companies in the Drug Manufacturers industry, placing it in the top 28.9%.
Is PT Kalbe Farma Tbk's ROC (Joel Greenblatt) % too high?
PT Kalbe Farma Tbk's current ROC (Joel Greenblatt) % of 30.43% is near median its 10-year median of 28.41. Over the past 10 years, this metric has ranged from a low of 20.99 to a high of 36.55. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. PT Kalbe Farma Tbk's value of 30.43% is 165.5% above this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #284 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's ROC (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #284 out of 983 companies for ROC (Joel Greenblatt) %. This puts PT Kalbe Farma Tbk in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. PT Kalbe Farma Tbk's value of 30.43% is 165.5% above this benchmark. Historically, PT Kalbe Farma Tbk's own ROC (Joel Greenblatt) % has ranged from 20.99 to 36.55 over the past decade. While the company's 10-year median is 28.41 vs. the industry median of 11.46, PT Kalbe Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current ROC (Joel Greenblatt) % of 30.43% is 165.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current ROC (Joel Greenblatt) % is 30.43%, which is near median its own 10-year median of 28.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.03 — trading 73% below its estimated fair value. The current ROC (Joel Greenblatt) % is 30.43%, which is near median its 10-year median of 28.41 and 165.5% above the Drug Manufacturers industry median of 11.46. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current ROC (Joel Greenblatt) % is 30.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 73% below its estimated GF Value™ of €0.10.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
ROC (Joel Greenblatt) %: 30.43% (near median its 10-year median of 28.41)
GF Value™: €0.10 vs. price of €0.03 (73% below fair value)
Industry Position: 165.5% above the Drug Manufacturers median (#284 of 983)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
